Alanine-scanning Mutagenesis of a Putative Substrate Recognition Site in Human Cytochrome P450 3A4
ROLE OF RESIDUES 210 AND 211 IN FLAVONOID ACTIVATION AND SUBSTRATE SPECIFICITY*

(Received for publication, October 22, 1996, and in revised form, December 23, 1996)

Greg R. Harlow Dagger and James R. Halpert

From the Department of Pharmacology and Toxicology, College of Pharmacy, University of Arizona, Tucson, Arizona 85721

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
Acknowledgments
REFERENCES


ABSTRACT

Alanine-scanning mutagenesis was performed on amino acid residues 210-216 of cytochrome P450 3A4, the major drug-metabolizing enzyme of human liver. Mutagenesis of this region, which has been proposed to align with the C-terminal ends of F-helices from cytochromes P450BM-3, P450terp, and P450cam, served as a test of the applicability of the substrate recognition site model of Gotoh (Gotoh, O. (1992) J. Biol. Chem. 267, 83-90) to P450 3A4. The results, using two steroid substrates, indicated that substitution of Ala for Leu210 altered the responsiveness to the effector alpha -naphthoflavone and the regioselectivity of testosterone hydroxylation. Replacement of Leu211 by Ala also decreased the stimulation by alpha -naphthoflavone, whereas mutations at residues 212-216 had little effect. The diminished flavonoid responses of the 210 and 211 mutants were observed over a wide range of progesterone and alpha -naphthoflavone concentrations. Further characterization was performed with the additional effectors beta -naphthoflavone, flavone, and 4-chromanone. The finding that P450 3A4 with one altered residue, Leu210 right-arrow Ala, can have both an altered testosterone hydroxylation profile and response to flavonoid stimulation provides evidence that the substrate binding and effector sites are at least partially overlapping.


INTRODUCTION

Human cytochrome P450 3A4 (P450 3A4)1 is capable of catalyzing the oxidative metabolism of a wide range of chemical compounds of very different structures (1). Of particular interest is the large number of drugs known to be metabolized by P450 3A4 (2). This enzyme may account for as much as 60% of the P450 in a human liver sample (3), making it one of the single most important human xenobiotic-metabolizing enzymes. Although 3A4 can accommodate a wide variety of structurally diverse substrates, it still exhibits remarkable regio- and stereoselectivity with many compounds. For example, the enzyme catalyzes the 2beta -, 6beta -, and 15beta -hydroxylation of testosterone, the 6beta - and 16alpha -hydroxylation of progesterone (4), the 1- and 4-hydroxylation of midazolam (5), and the M1-, M17-, and M21-oxidation of cyclosporin A (6). In addition to these properties, metabolic activities of enzymes of the P450 3A subfamily are modulated by naturally occurring phenolic compounds known as flavonoids, resulting in either the stimulation or inhibition of enzyme activity (7-11). Several sites for effector binding have been postulated based on the proposed mechanisms of action. Hypotheses include (a) alpha -NF increases the affinity of P450 for the substrate (12), (b) alpha -NF increases the affinity of P450 for reductase (10), (c) alpha -NF binds in the same pocket as the substrate and increases coupling efficiency (13), or (d) alpha -NF is an allosteric effector, binding at a distinct site and causing a conformational change in the substrate binding pocket (12-14).

Despite the wealth of information on the importance, regulation, and substrate specificity of the cytochrome P450 3A subfamily, structure-function analysis of these enzymes has not been rigorously approached. Unlike cytochromes P450 of family 2, 3A enzymes within or across species exhibit few dramatic substrate specificity differences that could provide obvious leads for site-directed mutagenesis of particular residues. Based on comparative sequence alignments and analogy with P450 101, the existence of six substrate recognition sites (SRSs) within family 2 has been proposed (15). Extensive analysis of P450 2B enzymes by this laboratory (16-23) and of enzymes in the P450 2A (24-26) and 2C (27-32) subfamilies have so far confirmed that virtually all amino acid residues and chimeric fragments identified as critical for the substrate specificity of P450 2 forms fall within or near the putative SRSs. To assess the applicability of the SRS model to the P450 subfamily 3A we have targeted P450 3A4 residues that are predicted (33) by a structure-based alignment to correspond to active site residues from P450BM-3, P450cam, and P450terp with the goal of identifying residues that form or influence the enzyme active site and/or effector binding site. We have chosen to start our analysis of P450 3A structure-function at a region that has been aligned by Hasemann et al. (33) with SRS-2. The SRS-2 residues 209 of P450s 2A4 and 2A5 (24-26, 34) and 206 of P450 2B1 (17) have been identified as substrate contact residues. The precise equivalents of these family 2 residues in P450BM-3, P450cam, or P450terp are uncertain due to a high degree of structural variability among the bacterial enzymes in these regions. We reasoned that verification of an equivalent SRS-like region in P450 3A4 in this difficult to align region would be an excellent indicator of the accuracy of the alignment and of whether other SRSs predicted by the alignment are likely to exist. We report here the use of alanine-scanning mutagenesis to examine the structure-activity relationships of seven residues from the P450 3A4 region analogous to SRS-2. Based on our analysis, a Leu right-arrow Ala substitution at residue 210 or 211 diminishes responsiveness to alpha -NF. This report details the first site-directed mutagenesis study of any P450 3A enzyme and provides definitive evidence for the location of P450 3A4 residues that influence flavonoid stimulation in a region shown to constitute part of the active site of several bacterial and mammalian cytochromes P450.


EXPERIMENTAL PROCEDURES

Materials

Primers for PCR amplification were obtained from the University of Arizona Macromolecular Structure Facility (Tucson, AZ) and National Biosciences, Inc. (Plymouth, MN). Restriction endonucleases and bacterial growth media were purchased from Life Technologies, Inc. CHAPS, progesterone, testosterone, alpha -NF, NADPH, and DOPC were purchased from Sigma. [4-14C]Progesterone was obtained from DuPont NEN. [4-14C]Testosterone was obtained from Amersham Life Science, Inc. HEPES was purchased from Calbiochem. Thin layer chromatography plates (silica gel, 250 mm, Si 250 PA (19C)) were purchased from Baker (Phillipsburg, NJ). All other reagents and supplies not listed were obtained from standard sources.

Cloning and Expression of P450 3A4

The P450 3A4 cDNA was isolated from human liver by PCR amplification of a first strand cDNA library created using the 3'-rapid amplification of cDNA ends kit (Life Technologies, Inc.) and total human liver RNA (Clontech; Palo Alto, CA). The N-terminal (5'-GTAGTGATGGCTCTCAGCCCAGACTTGGCC-3') and C-terminal (5'-GAAAATTCAGGCTCCACTTACGGTGCCATCCCTTGACTCAACCTT-3') primers were designed to amplify the entire 1.5-kilobase pair coding sequence (35). Reaction conditions were as follows: one cycle of 94 °C for 5 min, 45 °C for 5 min, and 72 °C for 5 min, followed by 29 cycles of 94 °C for 2 min, 45 °C for 2 min, and 72 °C for 2 min. To increase expression of the cDNA in Escherichia coli, N-terminal modifications were made by PCR using the primer 5'-GGGC<UNL>CCATGG</UNL>CTCTGTTATTAGCAGTTTTTCTGGTGCTCCT-3' as described previously (36) except for the incorporation of an NcoI site (underlined) to facilitate cloning rather than an NdeI site. Following modification, the 3A4 cDNA was cloned directly into the pCRII vector using the TA Cloning Kit (Invitrogen, San Diego, CA) and subsequently subcloned as an NcoI-KpnI fragment into the E. coli expression plasmid pSE380 (Pharmacia Biotech Inc.), creating pSE3A4. A BamHI site that originated from the pCRII multiple cloning site was deleted from pSE3A4 by cutting at the closely spaced SpeI sites and removing the short region containing the extra BamHI site followed by religation of the SpeI ends. The entire modified 3A4 insert was sequenced and was determined to be most similar to the 3A4 variant hPCN1 (37), differing only by a silent mutation (CTC right-arrow CTG) at the position that encodes Leu449.

Alanine-scanning Mutagenesis of Residues 210-216

Primers used to modify codons 210-216 were designed in the reverse orientation and are shown in Fig. 1. The forward primer used for PCR annealed to a position that corresponds to codons 146-152. PCR conditions were as follows: 1 cycle of 94 °C for 5 min, followed by 29 cycles of 94 °C for 1 min, 45 °C for 1 min, and 72 °C for 2 min. The resulting PCR products were digested with AatII and BamHI, creating a 128-base pair fragment that was used to replace the wild type segment in pSE3A4. The sequence of the entire 128-base pair mutagenized fragment was confirmed by sequencing.


Fig. 1. Primers used for site-directed mutagenesis. A section of the wild type P450 3A4 protein sequence is shown with codon numbering above and the DNA sequence directly below (BamHI site underlined). The oligonucleotides, designed in the reverse orientation, which were used to introduce individual alanine substitutions, are shown with the particular changes underlined.
[View Larger Version of this Image (21K GIF file)]


Preparation of Solubilized E. coli Membranes

CHAPS-solubilized membrane preparations were made essentially as described previously (38). Briefly, pSE3A4-containing E. coli DH5alpha cells were grown at 37 °C with 240-rpm shaking in 250 ml of liquid TB media (12 g of Bacto-tryptone, 24 g of Bacto-yeast extract, 4 ml/liter glycerol) to midlog phase before adding 1.0 mM isopropyl-1-thio-beta -D-galactopyranoside and 80 mg/ml delta -amino levulinic acid. Cells were harvested after an additional 48-h incubation at 30 °C with 190-rpm shaking. Membranes were solubilized in MOPS buffer (100 mM MOPS (pH 7.3), 10% glycerol, 0.2 mM dithiothreitol, 1 mM EDTA) containing 0.5% CHAPS. Recovery yields of 120-160 nmol of P450 3A4/liter of culture were routine as determined from reduced carbon monoxide difference spectra. P420 contamination was <5%.

Rat NADPH-P450 Reductase Expression and Purification

The cDNA encoding rat NADPH-P450 reductase was kindly provided by Dr. Todd Porter (College of Pharmacy, University of Kentucky, Lexington, KY). Reductase was expressed from a T7 expression plasmid, which was created by moving the XbaI-HindIII fragment from pOR262 (39) containing the N-terminally modified rat reductase with a fused ompA signal peptide and ribosome binding site into pET29a(+) (Novagen, Madison, WI). The resulting plasmid, pETOR262, was transformed into E. coli strain HMS174(DE3) (Novagen). Cells were grown at 37 °C with 240 rpm in 1-liter cultures of TB medium with 30 µg/ml kanamycin to midlog phase and then induced with 0.01 mM isopropyl-1-thio-beta -D-galactopyranoside and grown for an additional 20 h at 30 °C with 190-rpm shaking. Reductase was solubilized from E. coli membranes and purified on a 2',5'-ADP column as described previously (39).

Steroid Hydroxylase Assays

CHAPS-solubilized E. coli membrane preparations were used directly by reconstituting 10 pmol of P450 with 40 pmol of E. coli-expressed rat NADPH-P450 reductase, 10 pmol of rat cytochrome b5, and 0.1 mg/ml DOPC in a minimal volume; assays were performed for 5-15 min at 37 °C in 15 mM MgCl2, 50 mM HEPES buffer (pH 7.6), 0.1 mg/ml DOPC, 0.06% CHAPS, and 1 mM NADPH. Steroid and alpha -NF stock solutions were made in 100% methanol. Care was taken so that methanol concentrations in all reactions were equivalent and did not exceed 1% of the total reaction volume. Progesterone and alpha -NF concentrations varied according to the experiment and are described in the individual figure legends. Assays involving testosterone were performed using 25 µM testosterone with or without 25 µM alpha -NF. Identification of metabolites of progesterone (6beta -OH- and 16alpha -OH-progesterone) and testosterone (2beta -OH-, 6beta -OH-, and 16alpha -OH-testosterone) was by co-chromatography using authentic standards (Steraloids, Wilton, NH). A commercial source for 15beta -OH-testosterone was not available; identification of this metabolite was by relative mobility in TLC and comparison with the published values for TLC analysis of testosterone metabolites (40).


RESULTS

Alanine-scanning Mutagenesis of P450 3A4 Amino Acid Residues 210-216

The SRS model (15) for P450 family 2 enzymes has proven to be useful for predicting residues that may influence the geometry of the active site and thus affect enzymatic activity. In a search for residues that determine substrate specificity and flavonoid stimulation of human P450 3A4, a P450 family 3 enzyme, we made site-directed mutations over a short region in P450 3A4 that is predicted to align with the C-terminal end of helix F. This region contains the active site residues Thr185, Phe188, and Met185 from P450cam, P450terp, and P450BM-3, respectively (Fig. 2), and corresponds to SRS-2 in P450 family 2. Alanine-scanning mutagenesis (41) was used to individually change P450 3A4 amino acid residues 210-216 to alanine. All of the resulting alanine substitution mutants were efficiently expressed in an E. coli heterologous expression system at levels comparable with the N-terminally modified wild type construct (data not shown).


Fig. 2. A portion of the multiple sequence alignment by Hasemann et al. (33). Underlined residues indicate amino acids that help form the active site. P450 3A4 residues that were individually changed to alanine in this study are indicated with an asterisk below. The single-letter amino acid code is used with gaps in individual sequences indicated by a dot.
[View Larger Version of this Image (14K GIF file)]


Progesterone Hydroxylase Activities of P450 3A4 Wild Type and Alanine Substitution Mutants 210-216

-Solubilized membrane fractions from E. coli expressing P450 3A4 wild type or individual alanine substitution mutants were examined in reconstituted systems containing HEPES buffer with MgCl2, cytochrome b5, DOPC, and 0.06% CHAPS as described under "Experimental Procedures" for progesterone hydroxylase activity. Table I displays the results of these analyses. All mutants retained progesterone hydroxylase activity, forming two predominant metabolites, 6beta -OH and 16alpha -OH progesterone. In the absence of alpha -NF, the ratios of 6beta -hydroxylase to 16alpha -hydroxylase activities (beta /alpha ratios) of most of the mutants were similar to the wild type enzyme, the exception being mutants L210A and L211A, which had slightly elevated beta /alpha ratios.

Table I.

Effect of alpha -NF (25 µM) on progesterone hydroxylase activities of P450 3A4 wild type and site-directed mutant enzymes using 25 µM progesterone as substrate

Incubations were performed for 15 min as described under "Experimental Procedures."
3A4 sample MeOHa
 alpha -NFa
-Fold stimulation by alpha -NF
6beta -OH 16alpha -OH  beta /alpha 6beta -OH 16alpha -OH  beta /alpha 6beta -OH 16alpha -OH

Wild type 1.2 0.2 6.0 5.4 1.2 4.5 4.5 6.0
L210A 2.8 0.3 9.3 7.7 0.4 19.2 2.8 1.3
L211A 4.4 0.5 8.8 5.2 0.9 5.8 1.2 1.8
R212A 2.3 0.4 5.8 6.8 1.7 4.0 3.0 4.3
F213A 0.7 0.1 7.0 2.7 0.6 4.5 3.9 6.0
D214A 3.3 0.5 6.6 7.2 1.3 5.5 2.2 2.6
F215A 2.6 0.4 6.5 7.8 1.9 4.1 3.0 4.8
L216A 4.4 0.6 7.3 9.7 2.4 4.0 2.2 4.0

a  Values are nmol of product formed/min/nmol of P450 and are an average of duplicate determinations.

Previous studies have shown that, depending on the substrate and alpha -NF concentrations employed, individual metabolites from a single substrate can be differentially stimulated/inhibited by alpha -NF (13, 42). Table I demonstrates that the 16alpha -hydroxylase activity of wild type P450 3A4 is stimulated to a slightly greater extent by alpha -NF than the 6beta -hydroxylase activity of the enzyme. At a substrate concentration of 25 µM progesterone, wild type P450 3A4 had a beta /alpha ratio equal to 6.0 in the presence of the methanol control and 4.5 in the presence of 25 µM alpha -NF. One of the mutants, L210A, showed the opposite pattern of stimulation; i.e. 6beta -hydroxylase activity was stimulated more by alpha -NF than the 16alpha -hydroxylase activity. Because production of the 16alpha -OH-progesterone metabolite was only stimulated 1.3-fold (compared with 6.0-fold for wild type enzyme) in the presence of alpha -NF, the beta /alpha ratio was 19.2 for L210A as compared with 4.5 for wild type P450 3A4. Another interesting mutant is L211A, which showed less than 2-fold stimulation of both the 6beta - and 16alpha -hydroxylase activities by alpha -NF (1.2- and 1.8-fold, respectively). Alanine substitution mutants 212-216 maintained beta /alpha ratios more closely resembling the wild type enzyme in either the absence or presence of alpha -NF; for these mutants, alpha -NF always caused at least 2.2-fold stimulation and increased the 16alpha - more than the 6beta -hydroxylase activity.

The effect of alpha -NF on the observed progesterone hydroxylase activity was tested over a range of alpha -NF concentrations to determine whether the low levels of stimulation of the activities of the L210A and L211A mutants could be overcome by using higher concentrations of alpha -NF. When the progesterone concentration was kept at 25 µM and the alpha -NF concentration was increased to 200 µM, no further increase in progesterone hydroxylation was seen for P450 3A4 wild type, L210A, or L211A as compared with the stimulation by 25 µM alpha -NF (data not shown).

Kinetic Analysis of the 6beta -Hydroxylation of Progesterone in the Absence and Presence of alpha -NF

It was previously noted (12) that in the absence of alpha -NF the rates of progesterone 6beta -hydroxylation by rabbit and human liver microsomes gave nonlinear kinetics in a double reciprocal plot. Upon the addition of alpha -NF, however, the double reciprocal plot became linear. To determine whether the kinetics for L210A and L211A, the two mutants least responsive to alpha -NF stimulation, were similar to P450 3A4 wild type, the dependence of progesterone 6beta -hydroxylation on substrate concentration in the presence or absence of 25 µM alpha -NF was determined (Fig. 3). Double reciprocal plots showed that wild type P450 3A4, L210A, and L211A displayed nonlinear kinetics in the absence of alpha -NF. When 25 µM alpha -NF was included, the double reciprocal plot became linear.


Fig. 3. Lineweaver-Burk analysis of progesterone 6beta -hydroxylation in the absence (triangle ) or presence (bullet ) of 25 µM alpha -NF for P450 3A4 wild type (A), L210A (B), and L211A (C). Five-minute incubations were performed as described under "Experimental Procedures." Substrate concentrations used in these experiments were 10, 20, 40, 80, 160, and 320 µM progesterone, 1/[S] units are mM-1, and 1/V units represent (nmol of product/min/nmol of P450)-1. Solid linear regression lines (r2 >=  0.96) are shown for experimental results generated in the presence of 25 µM alpha -NF. In each plot, a dashed line has been drawn through the first two points representing data points generated in the absence of alpha -NF to demonstrate the nonlinearity of the data. Values represent an average of duplicate determinations.
[View Larger Version of this Image (10K GIF file)]


The kinetic analyses revealed that at high substrate concentrations the progesterone hydroxylase velocities obtained in the absence of alpha -NF approached those obtained in its presence. To better illustrate this phenomenon, the -fold stimulation by 25 µM alpha -NF was plotted as a function of progesterone concentration (Fig. 4). At high substrate concentrations (320 µM progesterone), essentially no stimulation of 6beta -hydroxylase activity by alpha -NF was seen for wild type P450 3A4, L210A, or L211A (Fig. 4A). As the progesterone concentration was lowered, wild type 3A4 became more responsive to stimulation by alpha -NF. P450 3A4 mutants L210A and L211A were less responsive than wild type to alpha -NF stimulation, especially at the lower concentrations of progesterone. For example, at 10 µM progesterone and 25 µM alpha -NF, the 6beta -hydroxylase activity of L210A was stimulated 4.3-fold and L211A was stimulated 2.6-fold as compared with the 10-fold stimulation of the wild type enzyme. Fig. 4B demonstrates a similar relationship between stimulation of progesterone 16alpha -hydroxylation and progesterone concentration. At 320 µM progesterone, no alpha -NF stimulation of 16alpha -hydroxylase activity was observed. As the progesterone concentration was decreased, the responsiveness of the wild type enzyme to alpha -NF stimulation increased. Thus, at 10 µM progesterone, the 16alpha -hydroxylase activity was stimulated 30-fold by alpha -NF. P450 L211A was stimulated only 6-fold at 10 µM progesterone, and L210A was stimulated just 2-fold.


Fig. 4. Relationship between -fold stimulation by alpha -NF and progesterone concentration. Stimulation of P450 3A4 wild type, L210A, and L211A activities by 25 µM alpha -NF as measured by their 6beta -hydroxylase (A) and 16alpha -hydroxylase activities (B) is shown. Values represent an average of duplicate determinations.
[View Larger Version of this Image (20K GIF file)]


Stereoselectivity of Testosterone Hydroxylation by Alanine Substitution Mutants

Table II summarizes the hydroxylase activities for wild type P450 3A4 and all of the mutants. As previously reported (4, 42), wild type P450 3A4 produces primarily three metabolites, 2beta -OH-, 6beta -OH-, and 15beta -OH-testosterone, with 6beta -hydroxylase accounting for 91% of the activity. All mutants retained testosterone hydroxylase activity, remaining primarily testosterone 6beta -hydroxylases. In the absence of alpha -NF, the metabolite percentages were approximately the same between the wild type enzyme and alanine substitution mutants 212-216. L210A had lower testosterone 2beta - and 15beta -hydroxylase activities than the wild type enzyme both in the absence and presence of alpha -NF. L210A produced an additional metabolite, 16alpha -OH-testosterone, at a rate (0.08 nmol/min/nmol) much higher than the wild type enzyme (<0.01 nmol/min/nmol). L211A, in the absence of alpha -NF, had a higher percentage of 2beta - and 15beta -hydroxylase activities than the wild type enzyme.

Table II.

Effect of alpha -NF (25 µM) on testosterone hydroxylase activities of P450 3A4 wild type and site-directed mutant enzymes using 25 µM testosterone as substrate.

Incubations were performed for 10 min as described under "Experimental Procedures."
3A4 sample MeOHa
 alpha -NFa
-Fold stimulation by alpha -NF
2beta -OH 6beta -OH 15beta -OH 2beta -OH 6beta -OH 15beta -OH 2beta -OH 6beta -OH 15beta -OH

Wild type 0.07 (5) 1.3 (91) 0.05 (4) 0.88 (17) 3.8 (74) 0.48 (9) 12.6 2.9 9.6
L210A 0.02 (1) 1.9 (97) 0.03 (2) 0.17 (4) 3.8 (94) 0.09 (2) 8.5 2.0 3.0
L211A 0.21 (9) 2.0 (84) 0.17 (7) 1.6 (34) 2.5 (53) 0.61 (13) 7.8 1.2 3.6
R212A 0.06 (4) 1.4 (93) 0.05 (3) 0.77 (15) 3.8 (77) 0.39 (8) 12.8 2.6 7.8
F213A 0.03 (2) 0.8 (96) 0.03 (2) 0.72 (17) 3.0 (72) 0.48 (11) 24 3.8 16.0
D214A 0.07 (5) 1.2 (91) 0.05 (4) 0.65 (18) 2.7 (73) 0.35 (9) 9.3 2.3 7.0
F215A 0.08 (5) 1.4 (92) 0.05 (3) 0.70 (13) 4.4 (80) 0.40 (7) 8.8 3.3 8.0
L216A 0.12 (5) 2.1 (91) 0.10 (4) 1.27 (15) 6.1 (74) 0.91 (11) 10.6 2.9 9.1

a  Values are nmol of product formed/min/nmol of P450 and are the mean of quadruplicate determinations. Numbers in parentheses represent the amount of metabolite as a percentage of the total (2beta -OH-, 6beta -OH-, and 15beta -OH-testosterone).

As with the unequal alpha -NF stimulation of wild type P450 3A4 progesterone 16alpha - and 6beta -hydroxylase activities, the testosterone 2beta - and 15beta -hydroxylase activities were preferentially stimulated 12.6- and 9.6-fold, respectively, as compared with the 2.9-fold stimulation of the testosterone 6beta -hydroxylase activity. In the presence of alpha -NF the testosterone metabolite profiles of mutants at positions 212-216 remained remarkably similar to the wild type enzyme. However, altered alpha -NF responsiveness of P450 3A4 mutants L210A and L211A was observed with testosterone, as illustrated in Fig. 5. L210A, because of decreased stimulation of 2beta - and 15beta -hydroxylase activities, maintained a high percentage of 6beta -OH-testosterone activity (94% versus the wild type 74%). In contrast, the P450 3A4 mutant L211A, because of decreased stimulation of 6beta -OH testosterone activity, displayed a lowered percentage of 6beta -OH-testosterone formation (53% versus the wild type 74%). F213A showed alpha -NF stimulation of 2beta - and 15beta -hydroxylase activities 2-fold greater than wild type enzyme, although the metabolite percentages in the presence of alpha -NF closely resembled the wild type profile. The remaining mutants maintained testosterone metabolite ratios and responsiveness to alpha -NF very similar to the wild type enzyme (Table II).


Fig. 5. Autoradiogram of the TLC showing the metabolites of testosterone formed by solubilized membrane preparations of P450 3A4 wild type and the alanine substitution mutants L210A and L211A in the absence (-) or presence (+) of 25 µM alpha -NF. Incubations were performed for 10 min as described under "Experimental Procedures." The testosterone concentration was 25 µM. One-third of the reaction was chromatographed. The parent compound and the major metabolites are labeled. Rates of formation of the major metabolites are given in Table II.
[View Larger Version of this Image (106K GIF file)]


Response of P450 3A4 Wild Type, L210A, and L211A to Partial or Modified Analogs of alpha -NF

A previous study (13) tested a number of partial or modified analogs of alpha -NF for their ability to modulate P450 3A4 activity. Using polycyclic aromatic hydrocarbons as test substrates, it was found that alpha -NF, flavone, and 4-chromanone could stimulate P450 3A4 activity and that beta -NF was a potent inhibitor of enzyme activity. In an attempt to ascertain whether the P450 3A4 mutants L210A and/or L211A displayed an altered response to stimulators/inhibitors other than alpha -NF, the effects of flavone, 4-chromanone, and beta -NF on progesterone hydroxylase activities were tested (Fig. 6). Similar to the previous study (13), flavone was an effective stimulator of P450 3A4 as measured by progesterone 6beta - and 16alpha -hydroxylase activities. However, rather than being an inhibitor, beta -NF was a mild stimulator of P450 3A4 progesterone hydroxylase activity (1.3- and 1.9-fold stimulation of the 6beta -OH and 16alpha -OH progesterone activities, respectively). In addition, in contrast to its stimulation of polycyclic aromatic hydrocarbon metabolism, 4-chromanone had largely no effect on progesterone hydroxylase activities. Interestingly, the P450 3A4 mutant L210A displayed near wild type levels of stimulation by flavone and beta -NF with respect to progesterone 6beta -hydroxylase activity; however, none of the compounds affected the 16alpha -hydroxylase activity of this mutant. The progesterone 6beta - and 16alpha -hydroxylase activities of L211A were affected by less than 2-fold for each of the stimulators/inhibitors tested.


Fig. 6. Compounds tested and the -fold stimulation observed of progesterone hydroxylase activities of P450 3A4 wild type, L210A, and L211A. A, chemical structures of the stimulators/inhibitors used in this study. ANF, alpha -naphthoflavone; BNF, beta -naphthoflavone. Shown are the effects of 25 µM test compound on progesterone 6beta -hydroxylation (B) or progesterone 16alpha -hydroxylation (C) using 25 µM progesterone as test substrate. Incubations were performed for 10 min as described under "Experimental Procedures." Values are an average of duplicate determinations.
[View Larger Version of this Image (23K GIF file)]



DISCUSSION

The results presented here describe for the first time the identification of certain key amino acid residues that play a role in substrate specificity and flavonoid stimulation of P450 3A4. The region selected for mutagenesis was predicted to be structurally similar to a portion of the F-helices of several bacterial enzymes of known crystal structure (33). However, even the alignment of proteins of known structure is subject to interpretation in this and several other key regions (for review, see Ref. 43). For example, a previous study of SRS-1 of P450 2C2 used a degenerated cassette to introduce random amino acid substitutions into a portion of the enzyme; this was helpful in confirming an alignment with P450cam (32). Targeting contiguous residues that are predicted to form SRSs has the potential of identifying both the residues that comprise the active site and, just as importantly, adjacent residues that do not contribute to the active site. For mutagenesis of the proposed SRS-2 region of P450 3A4, Ala was used as the substituting residue because of its small side chain, low tendency to distort the C-alpha backbone, and minimal electrostatic effects. Of the seven P450 3A4 residues targeted by Ala in this report, substitutions at positions 212 and 214-216 did not affect activity, suggesting that these residues do not effectively influence the substrate or effector binding sites. F213A displayed greater alpha -NF stimulation of testosterone hydroxylase activities than wild type P450 3A4. The remaining two mutants, L210A and L211A, exhibited altered basal activity and/or flavonoid responsiveness, suggesting that the substrate binding and effector sites are at least partially overlapping.

The presence of highly conserved residues can be an indication of the importance of a position to enzyme function. The two Leu residues at positions 210 and 211 of P450 3A4 are highly conserved, being present in P450s 3A1 and 3A2 from rat, 3A3 and 3A7 from human, 3A6 from rabbit, 3A8 from monkey, and 3A12 from dog. The exception is human P450 3A5, which instead has Phe at position 210. Substitution of Ala for Leu at residues 210 and 211 did not cause P450 3A4 to lose its preference for steroid 6beta -hydroxylation. This observation is in contrast to mutations at SRS-2 position 209 of 2A4 and 2A5 (24, 26, 44) and the corresponding position 206 of 2B1 (17), which conferred a radical shift in steroid hydroxylase specificities. Hydroxylation of steroids by P450 3A4, which is likely to have a very large active site, may be controlled more by the inherent chemical reactivity of the allylic 6-position than by steric constraints exerted by the enzyme, similar to P450 2B4-mediated hydroxylation of camphor. With P450 2B4, because of considerable movement of the substrate molecule in the active site, camphor hydroxylation occurred preferentially at sites predicted by chemical reactivities (45). Subtle effects on testosterone hydroxylation could be seen for the P450 3A4 mutants L210A and L211A at positions other than the 6-position of the substrate. For example, in the absence of stimulator, L210A had a lower percentage of testosterone 2beta - and 15beta -hydroxylation and increased testosterone 16alpha -hydroxylation compared with the wild type enzyme. Interestingly, substitution of Ala at the adjacent position, Leu211, had an opposite effect on the percentage of testosterone 2beta - and 15beta -hydroxylase activities, increasing them above the wild type levels. In the proposed alignment (Fig. 2), Leu210 aligns with active site residues Thr185 of P450cam and Phe188 of P450terp. In the alignment of Hasemann et al. (33) Leu210 of P450 3A4 is also aligned with position 209 of P450 2A4 and position 206 of P450 2B1. These results suggest that the alignment of P450 3A4 with P450terp, P450cam, and SRS-2 of P450 2A4 and P450 2B1 may be fairly accurate for this region. Met185 of P450BM-3 is not aligned with P450 3A4 position 210, although it is not aligned with the corresponding residues in P450terp or P450cam either. Another published alignment has the residues from positions 185 of P450cam, 188 of P450terp, and 185 of P450BM-3 aligned with position 206 of P450 2B1 (46).

It was previously noted with polycyclic aromatic hydrocarbon substrates (13) that alpha -NF differentially stimulates P450 3A4 hydroxylation of the narrower portions of the substrate. Our results with alpha -NF stimulation of P450 3A4 testosterone and progesterone hydroxylation follow this general rule; namely, the progesterone 16alpha -hydroxylase activity and the testosterone 2beta - and 15beta -hydroxylase activities (positions that are located at the narrow ends of both steroids) are stimulated more than hydroxylation at the 6beta (middle of the molecule) position. The two substitutions Leu210 right-arrow Ala and Leu211 right-arrow Ala seem to have opposite effects on differential stimulation of hydroxylation at the end versus the middle of the steroid; L210A shows less alpha -NF stimulation of end position hydroxylation, while L211A shows less stimulation of 6beta -hydroxylation. Previously, the importance of the exact residue identity at position 209 of P450 2A5 was studied by engineering nine individual amino acid substitutions (24). A more detailed analysis of positions 210 and 211 of P450 3A4 will require additional substitutions, additional substrates, and computer modeling (46).

The mutagenesis results, which identify residues that are able to influence stereospecificity of testosterone hydroxylation and effector activity, do not yet point to an obvious mechanism for alpha -NF stimulation. An early study with rabbit and human liver microsomes demonstrated that alpha -NF stimulation of progesterone 16alpha -hydroxylation and 17beta -estradiol 2-hydroxylation was largely due to a decreased Km with little change in Vmax (12). From their kinetic data the authors were not able to distinguish whether the interaction between enzyme and effector occurred at the active site or at a separate effector binding site. A more recent study (13) using P450 3A4 expressed in HepG2 cells presented evidence that phenanthrene and alpha -NF are present simultaneously in the active site and that the stimulation of phenanthrene metabolism by alpha -NF is a result of increased Vmax and not decreased Km. Again, the authors were unable to pinpoint an exact mechanism for alpha -NF action. Our kinetic results (Fig. 3), using the data points from the highest progesterone concentrations, are most consistent with alpha -NF stimulating P450 3A4 progesterone hydroxylation rates by lowering the Km and not by increasing the Vmax. The mechanism of alpha -NF stimulation of P450 3A4 remains to be elucidated, but we do now have evidence that single residue substitutions in an active site region of P450 3A4 can influence the ability to respond to effector, suggesting that the active site and the effector site are at least partially overlapping.

The finding that the structure-based alignment of Hasemann et al. (33) was accurate enough to predict the existence of key P450 3A4 residues in one of the most difficult to align regions suggests that the SRS model may be highly appropriate for the 3A subfamily. We anticipate that mutagenesis of the other more conserved SRS regions will be useful for elucidating the key residues that determine structure-activity relationships of the important P450 3A subfamily. Additional mutants with altered substrate specificities and/or altered responsiveness to flavonoids should help to determine whether substrate binding and effector sites are partially or completely overlapping.

The use of mutant enzymes that exhibit enhanced as well as diminished stimulation by alpha -NF may prove to be valuable in elucidating the mechanism of action of flavonoids on P450 3A enzymes. In order to understand the mechanistic basis for flavonoid action, wild type and mutant enzymes will need to be studied in terms of some of the key individual steps in the P450 cycle. For example, the stoichiometry of hydrogen peroxide or hydroxylated product formed/NADPH or oxygen consumed can give a measure of the degree of uncoupling observed in the presence or absence of effector. Recent studies with site-directed mutants of bacterial cytochromes P450cam and P450BM-3 provide an excellent illustration of the usefulness of these types of experiments in understanding the mechanistic basis of altered substrate metabolism by mutant enzymes (47, 48). The effects of cytochrome b5 will also be examined in light of the previous finding that some mutations at position 209 in SRS-2 of the P450 2A subfamily altered the coupling efficiency of electron transport to substrate oxidation (49).


FOOTNOTES

*   This work was supported by National Research Service Award GM17860 (to G. R. H.) and a pilot project from Southwest Environmental Health Sciences Center Grant ES06694. The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Dagger    To whom correspondence and reprint requests should be addressed. Tel.: 520-626-4489; Fax: 520-626-2466; E-mail: Harlow{at}tonic.pharm.arizona.edu.
1    The abbreviations used are: P450, cytochrome P450; SRS, substrate recognition site; alpha -NF, alpha -naphthoflavone; PCR, polymerase chain reaction; CHAPS, 3-[(3-cholamidopropyl)-dimethylammonio]-1-propanesulfonic acid; DOPC, dioleoylphosphatidylcholine; MOPS, 4-morpholinepropanesulfonic acid; reductase, NADPH-P450 oxidoreductase.

Acknowledgments

We thank Dr. Gilbert H. John for isolating the P450 3A4 cDNA and David Stepp for technical assistance.


REFERENCES

  1. Guengerich, F. P. (1992) FASEB J. 6, 745-748 [Abstract/Free Full Text]
  2. Guengerich, F. P. (1995) in in Cytochrome P450: Structure, Mechanism, and Biochemistry (Ortiz de Montellano, P. R., ed), pp. 473-535, Plenum Press, New York
  3. Guengerich, F. P. (1990) Chem. Res. Toxicol. 3, 363-371 [Medline] [Order article via Infotrieve]
  4. Waxman, D. J., Lapenson, D. P., Aoyama, T., Gelboin, H. V., Gonzales, F. J., and Korzekwa, K. (1991) Arch. Biochem. Biophys. 290, 160-166 [Medline] [Order article via Infotrieve]
  5. Kronbach, T., Mathys, D., Umeno, M., Gonzalez, F. J., and Meyer, U. A. (1989) Mol. Pharmacol. 36, 89-96 [Abstract]
  6. Aoyama, T., Yamano, S., Waxman, D. J., Lapenson, D. P., Meyer, U. A., Fischer, V., Tyndale, R., Inaba, T., Kalow, W., Gelboin, H. V., and Gonzalez, F. J. (1989) J. Biol. Chem. 264, 10388-10395 [Abstract/Free Full Text]
  7. Yun, C.-H., Okerholm, R. A., and Guengerich, F. P. (1993) Drug Metab. Dispos. 21, 403-409 [Abstract]
  8. Shimada, T., and Guengerich, F. P. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 462-465 [Abstract]
  9. Raney, K. D., Shimada, T., Kim, D., Groopman, J. D., Harris, T. M., and Guengerich, F. P. (1992) Chem. Res. Toxicol. 5, 202-210 [Medline] [Order article via Infotrieve]
  10. Huang, M.-T., Johnson, E. F., Muller-Eberhard, U., Koop, D. R., Coon, M. J., and Conney, A. H. (1981) J. Biol. Chem. 256, 10897-10901 [Abstract/Free Full Text]
  11. Korzekwa, K. R., and Jones, J. P. (1993) Pharmacogenetics 3, 1-18 [Medline] [Order article via Infotrieve]
  12. Schwab, G. E., Raucy, J. L., and Johnson, E. F. (1988) Mol. Pharmacol. 33, 493-499 [Abstract]
  13. Shou, M., Grogan, J., Mancewicz, J. A., Krausz, K. W., Gonzalez, F. J., Gelboin, H. V., and Korzekwa, K. R. (1994) Biochemistry 33, 6450-6455 [Medline] [Order article via Infotrieve]
  14. Ueng, Y., Shimada, T., Yamazaki, H., and Guengerich, F. P. (1995) Chem. Res. Toxicol. 8, 218-225 [Medline] [Order article via Infotrieve]
  15. Gotoh, O. (1992) J. Biol. Chem. 267, 83-90 [Abstract/Free Full Text]
  16. Liu, J., He, Y. A., and Halpert, J. R. (1996) Arch. Biochem. Biophys. 327, 167-173 [CrossRef][Medline] [Order article via Infotrieve]
  17. Luo, Z., He, Y., and Halpert, J. R. (1994) Arch. Biochem. Biophys. 309, 52-57 [CrossRef][Medline] [Order article via Infotrieve]
  18. Kedzie, K. M., Balfour, C. A., Escobar, G. Y., Grimm, S. W., He, Y., Pepperl, D. J., Regan, J. W., Stevens, J. C., and Halpert, J. R. (1991) J. Biol. Chem. 266, 22515-22521 [Abstract/Free Full Text]
  19. He, Y., Luo, Z., Klekotka, P. A., Burnett, V. L., and Halpert, J. R. (1994) Biochemistry 33, 4419-4424 [Medline] [Order article via Infotrieve]
  20. He, Y. A., Balfour, C. A., Kedzie, K. M., and Halpert, J. R. (1992) Biochemistry 31, 9220-9226 [Medline] [Order article via Infotrieve]
  21. Hasler, J. A., Harlow, G. R., Szklarz, G. D., John, G. H., Kedzie, K. M., Burnett, V. L., He, Y.-A., Kaminsky, L. S., and Halpert, J. R. (1994) Mol. Pharmacol. 46, 338-345 [Abstract]
  22. Harlow, G. R., and Halpert, J. R. (1996) Arch. Biochem. Biophys. 326, 85-92 [CrossRef][Medline] [Order article via Infotrieve]
  23. Halpert, J. R., and He, Y. (1993) J. Biol. Chem. 268, 4453-4457 [Abstract/Free Full Text]
  24. Iwasaki, M., Darden, T. A., Pedersen, L. G., Davis, D. G., Juvonen, R. O., Sueyoshi, T., and Negishi, M. (1993) J. Biol. Chem. 268, 759-762 [Abstract/Free Full Text]
  25. Juvonen, R. O., Iwasaki, M., and Negishi, M. (1991) J. Biol. Chem. 266, 16431-16435 [Abstract/Free Full Text]
  26. Lindberg, R. L. P., and Negishi, M. (1989) Nature 339, 632-634 [CrossRef][Medline] [Order article via Infotrieve]
  27. Hsu, M.-H., Griffin, K. J., Wang, Y., Kemper, B., and Johnson, E. F. (1993) J. Biol. Chem. 268, 6939-6944 [Abstract/Free Full Text]
  28. Imai, Y., and Nakamura, M. (1989) Biochem. Biophys. Res. Commun. 158, 717-722 [Medline] [Order article via Infotrieve]
  29. Kronbach, T., Kemper, B., and Johnson, E. F. (1991) Biochemistry 30, 6097-6102 [Medline] [Order article via Infotrieve]
  30. Kronbach, T., and Johnson, E. F. (1991) Biochemistry 266, 6215-6220
  31. Kaminsky, L. S., de Morais, S. M. F., Faletto, M. B., Dunbar, D. A., and Goldstein, J. A. (1992) Mol. Pharmacol. 43, 234-239 [Abstract]
  32. Straub, P., Lloyd, M., Johnson, E. F., and Kemper, B. (1993) J. Biol. Chem. 268, 21997-22003 [Abstract/Free Full Text]
  33. Hasemann, C. A., Kurumbail, R. G., Boddupalli, S. S., Peterson, J. A., and Deisenhofer, J. (1995) Curr. Biol. 2, 41-62
  34. Iwasaki, M., Juvonen, R., Lindberg, R., and Negishi, M. (1991) J. Biol. Chem. 266, 3380-3382 [Abstract/Free Full Text]
  35. Beaune, P. H., Umbenhauer, D. R., Bork, R. W., Lloyd, R. S., and Guengerich, F. P. (1986) Proc. Natl. Acad. Sci. U. S. A. 83, 8064-8068 [Abstract]
  36. Gillam, E. M., Baba, T., Kim, B., Ohmori, S., and Guengerich, F. P. (1993) Arch. Biochem. Biophys. 305, 123-131 [CrossRef][Medline] [Order article via Infotrieve]
  37. Gonzalez, F. J., Schmid, B. J., Umeno, M., McBride, O. W., Hardwick, J. P., Meyer, U. A., Gelboin, H. V., and Idle, J. R. (1988) DNA 7, 79-86 [Medline] [Order article via Infotrieve]
  38. John, G. H., Hasler, J. A., He, Y., and Halpert, J. R. (1994) Arch. Biochem. Biophys. 314, 367-375 [CrossRef][Medline] [Order article via Infotrieve]
  39. Shen, A. L., Porter, T. D., Wilson, T. E., and Kasper, C. B. (1989) J. Biol. Chem. 264, 7584-7589 [Abstract/Free Full Text]
  40. Waxman, D. J. (1991) Methods Enzymol. 206, 462-476 [Medline] [Order article via Infotrieve]
  41. Cunningham, B. C., and Wells, J. A. (1989) Science 244, 1081-1085 [Medline] [Order article via Infotrieve]
  42. Imaoka, S., Imai, Y., Shimada, T., and Funae, Y. (1992) Biochemistry 31, 6063-6069 [Medline] [Order article via Infotrieve]
  43. Von Wachenfeldt, C., and Johnson, E. F. (1995) in Cytochrome P450: Structure, Mechanism, and Biochemistry (Ortiz de Montellano, P. R., ed), pp. 183-223, Plenum Press, New York
  44. Iwasaki, M., Lindberg, R. L. P., Juvonen, R. O., and Negishi, M. (1993) Biochem. J. 291, 569-573 [Medline] [Order article via Infotrieve]
  45. White, R. E., McCarthy, M. B., Egeberg, K. D., and Sligar, S. G. (1984) Arch. Biochem. Biophys. 228, 493-502 [Medline] [Order article via Infotrieve]
  46. Szklarz, G. D., He, Y. A., and Halpert, J. R. (1995) Biochemistry 34, 14312-14322 [Medline] [Order article via Infotrieve]
  47. Loida, P. J., and Sligar, S. G. (1993) Biochemistry 32, 11530-11538 [Medline] [Order article via Infotrieve]
  48. Yeom, H., Sligar, S. G., Li, H., Poulos, T. L., and Fulco, A. J. (1995) Biochemistry 34, 14733-14740 [Medline] [Order article via Infotrieve]
  49. Juvonen, R. O., Iwasaki, M., and Negishi, M. (1992) Biochemistry 31, 11519-11523 [Medline] [Order article via Infotrieve]

©1997 by The American Society for Biochemistry and Molecular Biology, Inc.